曝露後予防投薬に関する知識、態度、実践への健康教育の影響
アスワン大学病院(エジプト)の医療従事者における曝露後予防投与に関する知識、態度、実践への健康教育の影響
The goal of this study is to learn whether a short education programme helps healthcare workers know more about post-exposure prophylaxis (PEP). PEP is medicine taken soon after contact with blood or body fluids, to lower the chance of infection. The study takes place at Aswan University Hospital in Egypt.
The main questions it aims to answer are:
Do healthcare workers know more about PEP three months after the programme than before it?
Do their attitudes toward PEP change?
Do their reported actions change, such as hepatitis B vaccination, use of PEP after an exposure, and finishing the prescribed course?
Participants are doctors, nurses, and laboratory and blood bank staff who work with patients or blood samples. They will:
Fill out a questionnaire before the programme.
Attend four 2-hour teaching sessions over two weeks.
Fill out the same questionnaire about three months later.
All participants receive the programme. There is no comparison group. Researchers will compare each person's answers before and after the programme to see what changed.
調査の概要
状態
介入・治療
詳細な説明
Design. This is a single-group, before-and-after (quasi-experimental) study. Each participant completes a baseline questionnaire before teaching and a follow-up questionnaire about three months after their group finishes teaching. Coded identifiers link the two questionnaires. The study ran from 30 January 2026 to 30 June 2026.
Setting and participants. The study took place at Aswan University Hospital in southern Upper Egypt. Staff were selected by stratified random sampling from three groups: physicians and clinically active academic staff, nurses, and laboratory and blood bank staff. Workers had to be actively employed in one of these groups, have worked at the hospital for at least six months, and give written informed consent. Non-clinical, housekeeping and auxiliary staff were excluded. In total, 380 workers were selected, and the target was 340 with complete before-and-after data.
Intervention. The programme had four 2-hour sessions over two weeks. Topics were:
Recognising and reporting an exposure.
First aid.
Assessing the source patient and the exposure.
Access to PEP in the hospital.
Hepatitis B vaccination.
HIV PEP timing and duration.
Adherence, counselling and follow-up testing.
The programme also covered the difference between HIV prophylaxis, hepatitis B prevention and hepatitis C follow-up. Teaching used slides, short videos, case scenarios, group discussion and printed materials. Physicians were taught in English, and nurses and laboratory staff in Arabic.
Measures. A questionnaire, adapted from published PEP surveys and available in Arabic and English, was used at both time points.
Primary outcome: change in a five-item knowledge score (0-5), calculated as follow-up score minus baseline score.
Secondary outcomes: change in a seven-item attitude and belief score (0-7), and individual practice indicators. These are self-reported hepatitis B vaccination, PEP use after exposure, time to starting PEP, and completion of the prescribed course.
Analysis. Paired changes are tested with the Wilcoxon signed-rank test for scores and the exact McNemar test for yes/no responses. Confidence intervals are reported for paired differences. The sample size was calculated to estimate a proportion with 5% precision, not to detect a difference between paired groups.
Changes from the original registration. The original record described nine knowledge questions and threshold-based classifications of knowledge, attitude and practice. The final analysis uses a five-item knowledge score, a seven-item attitude total without an overall classification, and individual practice indicators. The dates were updated to the actual start (30 January 2026) and completion (30 June 2026).
研究の種類
入学 (実際)
段階
- 適用できない
連絡先と場所
研究場所
-
-
-
Aswān、エジプト
- Aswan faculty of Medicine
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- HCWs at the selected departments (physicians, nurses and housekeepers).
- Age >18 years old and below 60 years old in both Genders.
- HCWs which have direct contact with blood and body fluids.
Exclusion Criteria:
- Age<18 years old and above 60 years old.
- Non-medical staff at Aswan university hospital.
- Health care workers which have no contact with blood or body fluids.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:支持療法
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Health Care workers
About 340 participants of heath care workers undergoing assessment of knowledge, attitude and practice about post-exposure prophylaxis among health care workers at Aswan university hospital, Egypt Then they will undergo lecturers about about post-exposure prophylaxis, then reassessment will be done after 3 months |
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Health Practice Change
時間枠:3 Months
|
Assessment of participants after taking health education lecturers about post-exposure prophylaxis regrading to knowledge, attitude and practice and this done by questionnaire as :The questionnaire consisted of three sections assessing knowledge, attitude, and practice regarding post-exposure prophylaxis (PEP). Section B assessed knowledge using nine close-ended questions, with adequate knowledge defined as ≥75% correct answers. Section C included seven items evaluating attitudes toward the importance and effectiveness of PEP, with scores ≥75% indicating a good attitude. Section D assessed PEP practices through nine questions, and good practice was defined as positive responses to more than 75% of items. |
3 Months
|
協力者と研究者
スポンサー
捜査官
- スタディチェア:Shaimaa Sayed Abdelrheem, M.D、Associate Professor of Public Health and Community Medicine, Faculty of medicine, Aswan University
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (実際)
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- Post-exposure prophylaxis
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。